

About the ImmunTraCkeR® test:

ImmunID has developed the immune molecular diagnostics test ImmunTraCkeR® which evaluates patient immune competence based on combinatorial T cell diversity. ImmunTraCkeR® is a unique CE-marked diagnostic test, which approaches the disease from the patient immune system's perspective. It is therefore patient-specific, unlike most molecular diagnostics tests, which are either drug- or disease-specific. ImmunTraCkeR® provides information on the patient immune profile, using it as a biomarker for clinical benefit or for risk in patients under immunotherapies. As a new immune companion diagnostic test, ImmunTraCkeR® should answer the urgent medical need for efficient patient stratification tools in melanoma and other solid cancers.

About ImmunID:

ImmunID has been a pioneer in the immune molecular diagnostic field since 2005. Its two clinical products ImmunTraCkeR® and ImmunIG® evaluate patient immune competence based on T and B cell repertoire diversity, respectively. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic for all immunotherapies and setting the general immune molecular diagnostics standard globally. ImmunID collaborates with leading clinical research centers and biopharmaceutical companies worldwide to further validate ImmunTraCkeR® as an immune companion diagnostic test for new immunotherapies and to widen clinical utility of its products. The company is ISO9001 certified and runs an ISO13485 accredited production and R&D facility in the MINATEC high-tech campus in Grenoble, France. In addition, ImmunID has applied for CAP accreditation / CLIA certification of its central lab to be able to provide ImmunTraCkeR® routinely to clinical patients in the United States.

www.immunid.com - Follow ImmunID on Twitter: <https://twitter.com/ImmunID>

Contact:

Bernhard Sxt

Chairman and CEO

contact@immunid.com

Phone: +33 438 785 770

